These technologies are a result of the company’s recent acquisition by Mayne Pharma Group. Mayne Pharma has applied pellet technology to a number of pharmaceuticals with modified release profiles, including Eryc (delayed release erythromycin), Doryx (delayed release doxycycline), Kadian (extended release morphine), Astrix (delayed release low-dose aspirin) and pulsed release diltiazem.
Metrics and Mayne offer two technologies for formulations: extrusion granulation that granulates API with excipients, which is extruded to form a core then coated by polymers, allowing potencies as high as 90%; and spheronization, which applies drug particles to a “seed” core with the aid of a binder. The core is then coated with a polymer and can provide potencies as high as 60%.
“At the end of the day, pharmaceutical science is all about making drugs as effective and tolerable as possible so that patients can experience both better health and a better quality of life when taking necessary medications,” said Dr. Brad Gold, vice president of pharmaceutical development at Metrics. “It’s exciting to offer pellet formulation to our clients – and to the patients they seek to help.”